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Drug Induced Liver Injury 
  
Drug – induced liver injury is uncommon and generally unpredictable. It accounts for <5% of 
cases of jaundice or acute hepatitis and fewer cases of chronic liver disease. Drug reactions 
produce an array of hepatic lesion that mimic all known hepato-biliary disease, from minor non-
specific changes in liver enzymes or ultra-structure to fatal hepatic necrosis, cirrhosis and liver 
cancer. Prevention of hepato-toxicity is an ethical and legal responsibility of individual doctors as 
well as society as a whole. 
 
In this brief review all issues related to drug induced hepatitis could not be addressed, therefore 
the emphasis would be on the important ones.  
 
Diagnosis: As there are no specific diagnostic tests, diagnosis of drug induced hepatitis requires 
clinical suspicion, a careful drug history, and consideration of the temporal relationships between 
drug ingestion and liver disease, and exclusion of the disorders. There is always an obligation for 
doctors and pharmacists to carefully inform their patients about the possibility of adverse 
reactions to any drugs that they are taking. Isoniazid, a drug known to be hepato-toxic for more 
than 25 years, is still usually associated with deaths from liver failure (1,2).  
 
It is clearly essential to exclude other liver disease before ascribing hepatic injury to a drug. Drug-
induced cholestasis should be considered when dilatation of the common bile duct has been 
excluded by hepato-biliary imaging. Extrahepatic features such as skin rash, eosinophilia and 
other organ involvement implicate adverse drug reactions, but as these features are present only 
in few cases, their absence is not helpful. Specific diagnostic tests for individual drugs-induced 
liver disease are not yet available, but in the case of dose dependent hepato-toxins like 
acetaminophen and aspirin, blood levels may be helpful. 
 
The criteria for temporal eligibility include relationship to onset, course of the reaction after 
discontinuing the drug (dechallenge), and response to readministration of the drug (rechallenge). 
Deliberate rechallenge is rarely indicated for logistic and ethical reasons (it can be hazardous) but 
inadvertent rechallenge may have occurred.  
 
In some cases, a liver biopsy may provide further clues to a drug etiology, such as 
disproportionate or zonal necrosis, microvesicular steatosis, bile duct injury, vascular lesions and 
a mixed inflammatory infiltrate that contains polymorphs and eosinophils as well as mononuclear 
cells (3). Currently, however, rechallenge remains the gold standard test for drug induced liver 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Factor Examples Influence on risk 
Age  
 
 
Gender 
 
 
Dose 
 
 
 
Genetic factors 
 
Alcohol abuse 
 
 
Obesity 
 
Fasting 
 
Diabetes mellitus 
Renal failure 
Isoniazid, Nitrofurantoin, Halothane 
Valproic acid. 
 
Methyldopa, Halothane, 
Nitrofurantoin. Azathioprine.  
 
Acetaminophen, AspirinMethotrexate, 
Vitamin A. 
 
 
Halothane, Phenytoin 
 
Acetaminophen 
Isoniazid, Methotrexate. 
 
Halothane hepatitis, Methotrexate 
 
Acetaminophen 
 
Methotrexate 
Tetracycline, Methotrexate 
Increases with age, >60 years. 
More common in young children. 
 
Acute and chronic hepatitis more in females. 
More common in males. 
 
Risk of hepatotoxicity related to blood levels. 
Total dose, dose frequency and duration of 
drug. 
 
Multiple cases in families. 
 
Lowers dose threshold 
Increases risk of liver injury. 
 
Increased risk of liver injury, hepatic fibrosis. 
 
Increased risk of hepatotoxicity. 
 
Increased risk of hepatic fibrosis. 
Increased risk of liver injury, hepatic fibrosis. 
 
 
Prevention: With the exception of acetaminophen hepatotoxicity, there is little effective treatment 
for drug induced liver disease. Hence, prevention and early detection of liver injury, together with 
prompt withdrawal of the offending agents are crucial. The majority of drugs associated with drug-
induced liver disease are idiosyncratic hepato-toxins. Polypharmacy should be avoided where 
possible, as drug reactions are more frequent when more than one agent is being taken. (4) 
 
Early detection of liver injury is critical. While prescribing hepatotoxic drug, patients should be 
warned to report non-specific features that may represent prodrome, such as unexplained 
nausea, malaise, right hypochondriac pain, lethargy or fever. These symptoms are an indication 
to perform liver tests and if the results suggest liver injury, to stop treatment immediately. Protocol 
screening with liver tests is often recommended, but its efficacy and cost-effectiveness is 
questionable.  
The classic example is Isoniazid, which causes some liver test abnormality in 30% of exposed 
subjects. Generally, it is recommended that the drug should be stopped if patient develops 
symptoms of liver injury or alanine aminotransferase (ALT) values exceed 250 IU/L or more than 
5 times the upper limit of normal. Rise in bilirubin and prothrombin time provides a clearer 
indication to stop or modify the therapy. Conversely, a rise in gamma-glutamyl transpeptidase 
(GGT) or minor elevation of serum alkaline phosphatase does not usually indicate liver injury. 
Thus, protocol screening is not routinely recommended, but it can be useful for agents such as 
isoniazid, pyrazinamide, valproate, halothane and retinoids (5).  
 
Management: Active management of drug-induced hepatotoxicity includes removal of the drug 
and administration of antidotes, anti-inflammatory and cytoprotective agents. In practice, it is 
usually confined to the discontinuation of hepatotoxic drugs. For ingested hepatotoxins like metal, 
poisonous mushrooms and acetaminophen, removal of unabsorbed drugs by aspirating stomach 
contents may be appropriate in initial hours. N-acetylcysteine is indicated as antidote for 
acetaminophen poisoning; whether it has a role in other types of acute hepatotoxicity is unclear.  
 
The management of drug hepatitis and cholestasis is otherwise symptomatic and supportive. In 
severe cases hepatic transplantation should be considered, while ursodeoxycholic acid has some 
promise for chronic cholestasis. (6,7). Corticosteroids have little role, although case reports at 
least show occasional effectiveness in few cases of hepatitis due to diclofenac and ketoconazole 
(5).  
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A Story of A Pharmacist In a Busy Pharmacy  
 
A pharmacist, who was working alone in a busy hospital pharmacy, received a stat order for oral 
clonidine 1 mg and levodopa 125 mg for a growth hormone stimulation test on an 8year-old child.  
 
Despite significant pressure from the stat order and a backlog of work, the pharmacist, who was 
unfamiliar with the test, took time to research the information and discovered that the correct test 
dose of clonidine for a pediatric patient was 0.15 mg/meter square.  
 
After calling the physician, the order was changed to clonidine 0.1 mg. Unfortunately, even 
successful outcomes like this one may not be widely appreciated if productivity is sacrificed to 
enhance patient safety. Nevertheless, numerous errors reported through the USP-ISMP 
Medication Errors Reporting Program have resulted when practitioners felt significant pressure to 
place productivity above patient safety, especially when faced with inadequate staffing. Institute 
for Safe Medication Practices (ISMP). 
Drug Expiration Date Clarification 
 
Expiration dating of original, unopened manufacturer drug packaging is based on both 
accelerated degradation studies and real-time stability data. Typically, newly marketed drugs will 
be limited to a maximum 2-year shelf life beyond packaging, even if extrapolated data from the 
accelerated degradation studies done with excessive temperature, humidity, and lighting 
conditions suggest stability beyond this time. The shelf-life can be extended based on further 
real-time data, with an outside limitation of 5 years. However, once the original packaging is 
opened, further claims on product stability and shelf life no longer apply (Anon, 1996).  
 
Guidelines for the labeling of expiration dates have been established by the United States 
Pharmacopeia. Labeling on all official drug product, nutritional, or dietary supplements must 
display the expiration date in a format which can be read and interpreted "by an ordinary 
individual under customary conditions of purchase and use". An exception is made for those drug 
products or nutritional supplements packaged for sale without a prescription where the labeling 
states no dosage limitations, and which is stable for not less than 3 years when stored under the 
prescribed conditions (USP/NF, 2000). The Convention also notes that when an expiration date is 
stated only in terms of the month and the year, this is a representation that the intended 
expiration date is the last day of the expressed month (USP/NF, 2000).  
 
Beyond-use dating establishes a reasonable time period for the patient to retain a drug product 
dispensed on prescription. The USP recommends such dating be limited to not later than (1) the 
expiration date on the manufacturer's container or (2) one year from the date the drug is 
dispensed, whichever is earlier. Other factors which the dispenser must consider prior to 
establishing this beyond-use date include: the nature of the drug; the characteristics of the 
container in which the product is dispensed; any unusual storage conditions expected to be 
encountered; and the expected length of therapy (USP/NF, 2000).  
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